Management

Dr. Moroney is one of the Company’s co-founders. Prior to that, Dr. Moroney held positions in the Department of Pharmacology, University of Cambridge, UK, as Assistant Professor in the Chemistry Department of the University of British Columbia, Vancouver, Canada, and as Associate in the Chemistry Department of the ETH in Zurich, Switzerland, where he also held a position as Lecturer. He was an Associate in the Harvard Medical School, Boston, USA, and an employee of ImmunoGen Inc., where he worked on the first generation of anti-cancer antibody conjugates.

Dr. Moroney studied chemistry in his native New Zealand, where he completed an MSc with 1st class honors and was a Commonwealth Scholar to the University of Oxford, where he was awarded a D.Phil. in Chemistry.

In 2002, Dr. Moroney received the German Cross of the Order of Merit by Dr. Johannes Rau, President of the Federal Republic of Germany, for his services to the biotechnology industry.

Dr. Moroney currently does not hold any other board memberships.

Jens Holstein joined MorphoSys from Fresenius Kabi AG, where he most recently served as Regional CFO for the region EME (Europe/Middle East) and as Managing Director of Fresenius Kabi Deutschland GmbH. Over the last almost 16 years at Fresenius he had held a variety of financial and general management positions. From 2006 to 2010, he was Regional Chief Financial Officer of Fresenius Kabi Asia Pacific Ltd., based in Hong Kong. Prior to this appointment, Mr. Holstein was Managing Director of Fresenius ProServe GmbH and Finance Director and Labor Director of the company's subsidiary Wittgensteiner Kliniken AG. Earlier positions within Fresenius included General Manager of hospitalia care GmbH, Commercial Manager of the Projects & Service business unit of Fresenius AG and Commercial Manager of hospitalia international GmbH. Prior to joining Fresenius, Mr. Holstein spent several years in the consulting industry, with positions in Frankfurt and London.

Mr. Holstein holds a Diploma in Business Administration from University of Münster.

He currently does not hold any other board memberships.

Dr. Schottelius joined MorphoSys from Genentech Inc., South San Francisco, where he served as the Director of Immunology, Tissue Growth & Repair Early Development and most recently as Medical Director, Immunology Development. Prior to his position at Genentech, Dr. Schottelius held science and management positions in immunology research at Berlex Biosciences, CA, USA, and Schering AG, Berlin, Germany.

Dr. Schottelius received his PhD and MD degrees from the University of Freiburg, Germany. Subsequently, he practiced medicine as a resident physician in gastroenterology at the Charité-Universitätsmedizin Berlin, Germany, and held a research fellowship from the Crohn’s & Colitis Foundation of America at the University of North Carolina before moving into the pharmaceutical industry.

Dr. Schottelius currently does not hold any other board memberships.

Dr. Sproll joined MorphoSys as R&D department head in 2000. In 2005, she was promoted to Chief Scientific Officer. Her current areas of responsibility include technology development, discovery, manufacturing, alliance management and intellectual property.

Before joining MorphoSys AG, Dr. Sproll held various R&D positions in the pharmaceutical industry, e.g. at the Vienna research facility of Boehringer Ingelheim and at E. Merck KGaA in Darmstadt, Germany, focusing on the discovery and development of antibody-based drugs and cancer vaccines.

Dr. Sproll studied Biology and was awarded a Doctor of Natural Sciences by the Technical University of Stuttgart, Germany. Before joining the industry, she held various research positions at different institutes of the Max-Planck Society in Tübingen, Germany.